hydrochlorothiazide has been researched along with Metabolic Syndrome in 26 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Following a 1-week screening withdrawal period, 482 patients (mean age 59 ± 10 years, 53% men) bearing a SBP at least 140 mmHg and/or DBP at least 90 mmHg plus metabolic syndrome (ATP-III criteria) were randomly allocated to a fixed-dose combination of zofenopril 30 mg plus hydrochlorothiazide 12." | 9.22 | Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic Synd ( Borghi, C; Napoli, C; Omboni, S, 2016) |
| "We studied the effects of treatment with olmesartan/amlodipine and olmesartan/hydrochlorothiazide on inflammatory and metabolic parameters (including new-onset diabetes as a secondary endpoint) in non-diabetic hypertensive patients with metabolic syndrome (MetS)." | 9.15 | Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. ( Comi-Diaz, C; Martinez-Martin, FJ; Pedrianes-Martin, P; Peiro-Martinez, I; Rodriguez-Rosas, H; Soriano-Perera, P, 2011) |
| "The impact of an ARB, with or without hydrochlorothiazide (HCTZ), on glycaemic factors and the risk for developing diabetes in hypertensive patients with the metabolic syndrome have not been fully assessed." | 9.14 | A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome. ( Bastien, N; Hamet, P; Longo, N; Racine, N; Sampalis, JS, 2010) |
| "Telmisartan (Micardis, Pritor), a highly selective angiotensin II (AII) type 1 (AT1) receptor antagonist, is approved for the treatment of hypertension, either as monotherapy or in combination with other antihypertensive agents." | 8.83 | Telmisartan: a review of its use in the management of hypertension. ( Battershill, AJ; Scott, LJ, 2006) |
| " Although blood levels of potassium, hemoglobin A1c and uric acid (UA) significantly increased after 3 months for all of the patients, none of the patients showed serious adverse effects." | 6.77 | Efficacy and safety of a single-pill fixed-dose combination of high-dose telmisartan/hydrochlorothiazide in patients with uncontrolled hypertension. ( Arimura, T; Fujisawa, K; Inoue, A; Kuwano, T; Matsunaga, E; Mitsutake, R; Miura, S; Morii, J; Nagata, I; Norimatsu, K; Saku, K; Shiga, Y; Shimizu, T; Shirotani, T; Uehara, Y, 2012) |
| " Following a 1-week screening withdrawal period, 482 patients (mean age 59 ± 10 years, 53% men) bearing a SBP at least 140 mmHg and/or DBP at least 90 mmHg plus metabolic syndrome (ATP-III criteria) were randomly allocated to a fixed-dose combination of zofenopril 30 mg plus hydrochlorothiazide 12." | 5.22 | Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic Synd ( Borghi, C; Napoli, C; Omboni, S, 2016) |
| "A total of 439 hypertensive patients with metabolic syndrome and/or diabetes mellitus were randomized to 2 groups: group 1--ramipril (ACE-I) or perindopril and group 2--losartan (ARB)." | 5.19 | Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the M E D I N A study). ( Soucek, M; Spinar, J; Vitovec, J, 2014) |
| "We studied the effects of treatment with olmesartan/amlodipine and olmesartan/hydrochlorothiazide on inflammatory and metabolic parameters (including new-onset diabetes as a secondary endpoint) in non-diabetic hypertensive patients with metabolic syndrome (MetS)." | 5.15 | Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. ( Comi-Diaz, C; Martinez-Martin, FJ; Pedrianes-Martin, P; Peiro-Martinez, I; Rodriguez-Rosas, H; Soriano-Perera, P, 2011) |
| "The impact of an ARB, with or without hydrochlorothiazide (HCTZ), on glycaemic factors and the risk for developing diabetes in hypertensive patients with the metabolic syndrome have not been fully assessed." | 5.14 | A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome. ( Bastien, N; Hamet, P; Longo, N; Racine, N; Sampalis, JS, 2010) |
| "This post hoc analysis of a 7-week, randomized, double-blind trial evaluated the efficacy and safety of initial irbesartan/hydrochlorothiazide treatment in 468 patients with severe, uncontrolled, hypertension (diastolic blood pressure [DBP] > or =100 mm Hg) at high cardiovascular risk." | 5.14 | Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors. ( Franklin, SS; Neutel, JM, 2010) |
| " STAR-LET was a 6-month extension of the Study of Trandolapril/Verapamil SR and Insulin Resistance (STAR), which assessed the effects of a fixed-dose renin-angiotensin system inhibitor (RASI)/hydrochlorothiazide (HCTZ) combination on changes in 2-hour oral glucose tolerance test (OGTT) results." | 5.13 | Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. ( Bacher, P; Bakris, G; Champion, A; Molitch, M; Sarafidis, P; Sowers, JR; Zhou, Q, 2008) |
| "The aim of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation study was to compare the long-term effect of the commonly used inexpensive medication with a low-dose diuretic (hydrochlorothiazide), alone or in combination with a beta-adrenoceptor (atenolol), with that of more modern but also more expensive antihypertensive treatment with an angiotensin-II-receptor blocker (candesartan), alone or in combination with a calcium antagonist (felodipine), and to do so in newly diagnosed patients with primary hypertension." | 5.10 | Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). ( Alaupovic, P; Carlberg, B; Lindholm, LH; Persson, M; Samuelsson, O; Svensson, A, 2003) |
| "Telmisartan (Micardis, Pritor), a highly selective angiotensin II (AII) type 1 (AT1) receptor antagonist, is approved for the treatment of hypertension, either as monotherapy or in combination with other antihypertensive agents." | 4.83 | Telmisartan: a review of its use in the management of hypertension. ( Battershill, AJ; Scott, LJ, 2006) |
| "Experiments were carried out to investigate whether diuretics (hydrochlorothiazide + furosemide) impact on the effects of a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor on glucose metabolism and blood pressure (BP) in metabolic syndrome SHR/NDmcr-cp(+/+) rats (SHRcp)." | 3.83 | Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome. ( Fujisawa, Y; Hitomi, H; Kittikulsuth, W; Nakano, D; Nishiyama, A; Rafiq, K; Rahman, A; Sohara, E; Sufiun, A; Uchida, S, 2016) |
| " Potassium supplementation improves their insulin resistance and hypertension, whereas allopurinol reduces serum levels of uric acid and ameliorates hypertension, hypertriglyceridemia, hyperglycemia, and insulin resistance." | 3.74 | Thiazide diuretics exacerbate fructose-induced metabolic syndrome. ( Johnson, RJ; Mu, W; Nakagawa, T; Reungjui, S; Roncal, CA; Sirivongs, D; Srinivas, TR, 2007) |
| " Although blood levels of potassium, hemoglobin A1c and uric acid (UA) significantly increased after 3 months for all of the patients, none of the patients showed serious adverse effects." | 2.77 | Efficacy and safety of a single-pill fixed-dose combination of high-dose telmisartan/hydrochlorothiazide in patients with uncontrolled hypertension. ( Arimura, T; Fujisawa, K; Inoue, A; Kuwano, T; Matsunaga, E; Mitsutake, R; Miura, S; Morii, J; Nagata, I; Norimatsu, K; Saku, K; Shiga, Y; Shimizu, T; Shirotani, T; Uehara, Y, 2012) |
| "Hypertensive patients with the cardiometabolic syndrome (CMS) are at increased risk for type 2 diabetes and cardiovascular disease." | 2.73 | Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome. ( Deedwania, PC; Fonseca, VA; Haffner, SM; Hsueh, WA; Keeling, L; Sica, DA; Sowers, JR; Zappe, DH, 2008) |
| "Thirty percent had type 2 diabetes mellitus, 46% had metabolic syndrome, and baseline blood pressure was 154." | 2.71 | The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. ( Bakris, GL; Cushman, WC; Ferdinand, KC; Neutel, JM; Ofili, EO; Saunders, E; Sowers, JR; Weber, MA, 2005) |
| "Chlorthalidone, 12." | 1.39 | Obesity and hypertension: It's about more than the numbers. ( Ferdinand, KC, 2013) |
| "The metabolic syndrome is a cluster of cardiovascular risk factors leading to an increased risk for the subsequent development of diabetes and cardiovascular morbidity and mortality." | 1.34 | Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. ( Bramlage, P; Kintscher, U; Paar, WD; Thoenes, M; Unger, T, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (38.46) | 29.6817 |
| 2010's | 16 (61.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferdinand, KC | 3 |
| Spinar, J | 1 |
| Vitovec, J | 1 |
| Soucek, M | 1 |
| Schlimpert, V | 1 |
| Ghiadoni, L | 1 |
| Bruno, RM | 1 |
| Cartoni, G | 1 |
| Stea, F | 1 |
| Magagna, A | 1 |
| Virdis, A | 1 |
| Grassi, D | 1 |
| Ferri, C | 1 |
| Taddei, S | 1 |
| Toyoda, S | 1 |
| Inami, S | 1 |
| Kato, T | 1 |
| Tsukada, K | 1 |
| Nakamoto, A | 1 |
| Kikegawa, Y | 1 |
| Suzuki, A | 1 |
| Anraku, Y | 1 |
| Node, K | 1 |
| Inoue, T | 1 |
| Rahman, A | 1 |
| Kittikulsuth, W | 1 |
| Fujisawa, Y | 1 |
| Sufiun, A | 1 |
| Rafiq, K | 1 |
| Hitomi, H | 1 |
| Nakano, D | 1 |
| Sohara, E | 1 |
| Uchida, S | 1 |
| Nishiyama, A | 1 |
| Napoli, C | 1 |
| Omboni, S | 1 |
| Borghi, C | 2 |
| Zappe, DH | 1 |
| Sowers, JR | 4 |
| Hsueh, WA | 1 |
| Haffner, SM | 1 |
| Deedwania, PC | 1 |
| Fonseca, VA | 1 |
| Keeling, L | 1 |
| Sica, DA | 1 |
| Racine, N | 1 |
| Hamet, P | 1 |
| Sampalis, JS | 1 |
| Longo, N | 1 |
| Bastien, N | 1 |
| Franklin, SS | 1 |
| Neutel, JM | 3 |
| Ntaios, G | 1 |
| Savopoulos, C | 1 |
| Chatzopoulos, S | 1 |
| Mikhailidis, D | 1 |
| Hatzitolios, A | 1 |
| Martinez-Martin, FJ | 1 |
| Rodriguez-Rosas, H | 1 |
| Peiro-Martinez, I | 1 |
| Soriano-Perera, P | 1 |
| Pedrianes-Martin, P | 1 |
| Comi-Diaz, C | 1 |
| Thomopoulos, C | 1 |
| Tsioufis, C | 1 |
| Makris, T | 1 |
| Stefanadis, C | 1 |
| McInnes, GT | 1 |
| Shiga, Y | 1 |
| Miura, S | 1 |
| Mitsutake, R | 1 |
| Norimatsu, K | 1 |
| Nagata, I | 1 |
| Arimura, T | 1 |
| Shimizu, T | 1 |
| Morii, J | 1 |
| Kuwano, T | 1 |
| Uehara, Y | 1 |
| Inoue, A | 1 |
| Shirotani, T | 1 |
| Fujisawa, K | 1 |
| Matsunaga, E | 1 |
| Saku, K | 1 |
| Komers, R | 1 |
| Rogers, S | 1 |
| Oyama, TT | 1 |
| Xu, B | 1 |
| Yang, CL | 1 |
| McCormick, J | 1 |
| Ellison, DH | 1 |
| Cicero, AF | 1 |
| De Sando, V | 1 |
| Izzo, R | 1 |
| Vasta, A | 1 |
| Trimarco, A | 1 |
| Lindholm, LH | 1 |
| Persson, M | 1 |
| Alaupovic, P | 1 |
| Carlberg, B | 1 |
| Svensson, A | 1 |
| Samuelsson, O | 1 |
| Saunders, E | 2 |
| Bakris, GL | 2 |
| Cushman, WC | 2 |
| Ofili, EO | 2 |
| Weber, MA | 2 |
| Battershill, AJ | 1 |
| Scott, LJ | 1 |
| Leonova, MV | 1 |
| Demidova, MA | 1 |
| Tarasov, AV | 1 |
| Belousov, IuB | 1 |
| Kintscher, U | 1 |
| Bramlage, P | 1 |
| Paar, WD | 1 |
| Thoenes, M | 1 |
| Unger, T | 1 |
| Reungjui, S | 1 |
| Roncal, CA | 1 |
| Mu, W | 1 |
| Srinivas, TR | 1 |
| Sirivongs, D | 1 |
| Johnson, RJ | 1 |
| Nakagawa, T | 1 |
| Parhofer, KG | 1 |
| Münzel, F | 1 |
| Krekler, M | 1 |
| Bakris, G | 1 |
| Molitch, M | 1 |
| Zhou, Q | 1 |
| Sarafidis, P | 1 |
| Champion, A | 1 |
| Bacher, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan and Hydrochlorothiazide Combined and Alone, in Patients With Metabolic Syndrome[NCT00170937] | Phase 4 | 507 participants | Interventional | 2004-11-30 | Completed | ||
| 52 Week Study to Evaluate the Effects of LOSARTAN 50 mg, 100 mg, 100/12.5 mg HCTZ, 100/25 mg HCTZ on Metabolic Parameters, Blood Pressure and Safety in Hypertensive Patients With Metabolic Syndrome[NCT00546052] | Phase 3 | 1,738 participants (Actual) | Interventional | 2005-09-01 | Completed | ||
| Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine[NCT00564057] | Phase 4 | 30 participants (Anticipated) | Interventional | 2007-09-30 | Recruiting | ||
| Uric Acid and Hypertension in African Americans[NCT00241839] | Phase 3 | 150 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Absolute Change in C Reactive Protein Between Baseline and 52 week assessments: C Reactive Protein 52 weeks - C Reactive Protein Baseline. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mg/L (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -0.36 |
Absolute Change in Uric Acid Between Baseline and 52 week assessments: Uric Acid 52 weeks - Uric Acid Baseline. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mmol/L (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -19.17 |
Absolute change in Body Mass Index Baseline and 52 week assessments (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Kg/m2 (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -7.3 |
Absolute change in Diastolic Blood Pressure between baseline and 52 week assessments. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mm Hg (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -9.84 |
Absolute Change in Fasting Blood Glucose Measurements between Baseline and 52 week assessments. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mmol/L (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | 0.02 |
Absolute Change in Hemoglobin A1c between 52 week measurement and baseline value. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent (Median) |
|---|---|
| Losartan +/- Hydrochlorothiazide | 0.04 |
Absolute change in Systolic Blood Pressure between baseline and 52 week assessments. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mm Hg (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -16.95 |
Absolute change in Waist Circumference between baseline and 52 week assessments (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | cm (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -1.28 |
Percent Change in HDL-C Between Baseline and 52 week assessments: 100% x [(HDL-C 52 Weeks - HDL-C 52 Baseline) / (HDL-C Baseline)]. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent Change (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | 0.21 |
Percent Change in LDL-C Between Baseline and 52 week assessments: 100% x [(LDL-C 52 Weeks - LDL-C Baseline) / (LDL-C Baseline)]. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent Change (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -1.49 |
Percent Change in Total Cholesterol Between Baseline and 52 week assessments: 100% x [(Total Cholesterol 52 weeks - Total Cholesterol Baseline) / (Total Cholesterol Baseline)]. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent Change (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -2.98 |
Percent Change in Triglycerides Between Baseline and 52 week assessments: 100% x [(Triglycerides 52 Weeks - Triglycerides Baseline) / (Triglycerides Baseline)]. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent Change (Median) |
|---|---|
| Losartan +/- Hydrochlorothiazide | 1.09 |
Target Blood Pressure defined as Systolic Blood Pressure/Diastolic Blood Pressure ≤ 140/90 mm Hg at 52 weeks (NCT00546052)
Timeframe: 52 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Achieved Target Blood Pressure | Did NOT achieve target Blood Pressure | |
| Overall Intend to Treat | 1200 | 514 |
| Overall Per Protocol | 1200 | 311 |
| Overall Total | 1200 | 538 |
"The Diastolic BP was taken at Baseline and after 8-10 weeks of treatment or placebo while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol / placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 3.44 |
| B (Placebo) | -0.83 |
Subjects had 24 hr blood pressure monitoring (ABPM) at baseline and treatment end. The readings were averaged and the changes from baseline to treatment end were compared. (NCT00241839)
Timeframe: Baseline and end of treatment (8-10 weeks on allopurinol / placebo)
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | -5.9 |
| B (Placebo) | 0.90 |
"The systolic BP was taken at Baseline and after 8-10 weeks of treatment on placebo, while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol or placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 0.21 |
| B (Placebo) | -0.95 |
Subjects on allopurinol are expected to lower their uric acid levels relative to placebo. (NCT00241839)
Timeframe: Baseline UA levels compared to end of treatment levels (8-10 weeks on allopurinol / placebo)
| Intervention | mg/dl (Mean) |
|---|---|
| A (Allopurinol) | 2.29 |
| B (Placebo) | 0.14 |
2 reviews available for hydrochlorothiazide and Metabolic Syndrome
| Article | Year |
|---|---|
Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: a systematic review and metaanalysis.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Clinical Trials as Topic; Fibric Acids; Homocys | 2011 |
Telmisartan: a review of its use in the management of hypertension.
Topics: Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Type 2; Drug | 2006 |
14 trials available for hydrochlorothiazide and Metabolic Syndrome
| Article | Year |
|---|---|
Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the M E D I N A study).
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2014 |
Combination therapy with lercanidipine and enalapril reduced central blood pressure augmentation in hypertensive patients with metabolic syndrome.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel B | 2017 |
Choice of Antihypertensive Combination Therapy Based on Daily Salt Intake.
Topics: Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Blood Pressure; D | 2015 |
Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic Synd
Topics: Aged; Biphenyl Compounds; Captopril; Female; Humans; Hydrochlorothiazide; Irbesartan; Male; Metaboli | 2016 |
Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes | 2008 |
A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Glu | 2010 |
Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Body Mas | 2010 |
Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study.
Topics: Adiponectin; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; C-Reactive Protein; C | 2011 |
Efficacy and safety of a single-pill fixed-dose combination of high-dose telmisartan/hydrochlorothiazide in patients with uncontrolled hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; B | 2012 |
Effect of a combined nutraceutical containing Orthosiphon stamineus effect on blood pressure and metabolic syndrome components in hypertensive dyslipidaemic patients: a randomized clinical trial.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calc | 2012 |
Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).
Topics: Antihypertensive Agents; Apolipoproteins; Atenolol; Blood Glucose; Blood Pressure; Drug Therapy, Com | 2003 |
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabete | 2005 |
Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2007 |
Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study.
Topics: Analysis of Variance; Chi-Square Distribution; Diabetes Mellitus; Diuretics; Female; Glucose Toleran | 2008 |
10 other studies available for hydrochlorothiazide and Metabolic Syndrome
| Article | Year |
|---|---|
Obesity and hypertension: It's about more than the numbers.
Topics: Antihypertensive Agents; Chlorthalidone; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug | 2013 |
[Optimizing antihypertensive therapy].
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; I | 2015 |
Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome.
Topics: Administration, Oral; Animals; Blood Pressure; Diuretics; Furosemide; Hydrochlorothiazide; Hypertens | 2016 |
The 'pyrrhic victory' of amlodipine over hydrochlorothiazide in the OLAS Study.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Body Mass Index; Comorbidity; Drug Therapy, Com | 2011 |
The effect of antihypertensive agents in people at high risk of cardiovascular disease and diabetes: a view through smoke and mirrors.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Comorbidity; Diabetes | 2011 |
Enhanced phosphorylation of Na(+)-Cl- co-transporter in experimental metabolic syndrome: role of insulin.
Topics: Animals; Blood Pressure; Cells, Cultured; Chromones; HEK293 Cells; Humans; Hydrochlorothiazide; Hype | 2012 |
Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.
Topics: Adult; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphe | 2006 |
[Hypotensive, organoprotective, and metabolic effects of Angiotensin converting enzyme inhibitor moexipril in women with postmenopausal syndrome].
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Delayed-Action Preparations; | 2006 |
Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
Topics: Abdominal Fat; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Comp | 2007 |
Thiazide diuretics exacerbate fructose-induced metabolic syndrome.
Topics: Allopurinol; Animals; Blood Pressure; Body Weight; Diuretics; Fructose; Gout Suppressants; Hydrochlo | 2007 |